Björn Erikstein

Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment

Anthony Howell, J.F.R. Robertson, J. Albano et al. · Journal of Clinical Oncology · 2002 · 669 citations

Medicine, Oncology, Pharmacology +14

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial

Jonas Bergh, Tom Wiklund, Björn Erikstein et al. · The Lancet · 2000 · 342 citations

Medicine, Oncology, Pharmacology +17

Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer

Per Eystein Lønning, Jürgen Geisler, Lars Erik Krag et al. · Journal of Clinical Oncology · 2005 · 294 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Topoisomerase IIα Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in <i>HER-2/neu</i>–Amplified Breast Cancer: Scandinavian Breast Group Trial 9401

Minna Tanner, Jorma Isola, Tom Wiklund et al. · Journal of Clinical Oncology · 2006 · 255 citations · Full text

Medicine, Oncology, Pharmacology +16

Genetic variants of CYP19 (aromatase) and breast cancer risk

Vessela N. Kristensen, Nobuhiro Harada, Noriko Yoshimura et al. · Oncogene · 2000 · 166 citations

Life Sciences, Genetics, Oncology +14